Back to homepage

Immunology

Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children

Authors: Saleh al-Alaiyan, Paul Pollack, Gerard F Notario

The peak season of respiratory syncytial virus (RSV) infections in warmer climates may extend beyond the typical five-month RSV season of temperate regions. This study aimed to assess the safety, immunogenicity, and pharmacokinetics of an extended seven-dose regimen of palivizumab in children at high risk for serious infection by the RSV.

More

Willingness of European healthcare workers to undergo vaccination against seasonal influenza: current situation and suggestions for improvement

Authors: George Kassianos

Uptake of vaccination against seasonal influenza in healthcare
workers (HCWs) is, in general, low (vaccine coverage of 6–54%), as is awareness of its importance, and has been decreasing in most European Union (EU) countries in recent years. This article clarifies the current situation and makes suggestions for improvement.

More

Vaccination against meningitis B: is it worth it?

Authors: Peter English

When a new vaccine is licensed having passed the tests for efficacy and safety, governments who have to pay for it to be used, as in the UK, will carry out a careful economic appraisal before making it generally available. In this challenging article, Dr Peter English discusses whether or not a new vaccine for meningitis that has just been licensed and that could save lives is actually worth it.

More